The Prognostic Significance Of GPS/MGPS System In Advanced Non-small Cell Lung Cancer Patients

Backgrounds：With the deepening study on the individualized treatment of cancerpatients, it was found that patient’s own factors, especially the decline ofnutrition and performance Status, are independent adverse prognosticfactors in patients with cancer. The GPS/mGPS system can objectivelyassess nutritional status of cancer patient. There are a small number ofreports for the GPS/mGPS system and prognosis of lung cancer, most ofthem come from foreign countries, only two reports with small samplesize from the same sample in our country.Objectives：The purpose of the study was to evaluate the prognostic significanceof GPS/mGPS system in advanced NSCLC patients treated withplatinum-based first-line chemotherapy.Methods:1. A total of207cases of newly diagnosed advanced NSCLCpatients in Cancer Center, The First Hospital of Jilin University, between1st March,2011and1st September,2014, were enrolled in this study, anda retrospective analysis was conducted.144cases (69.6%) were male, and63cases (30.4%) were female, the ratio of male to female was2.29to1.81cases (39.1%) were not less than60years old, and126cases (60.9%)were under60years old. The median was58years (ranged from35yearsto78years).2. Three~five milliliters of peripheral venous blood were drawnfrom each patient at the time of initial diagnosis, the blood wascentrifuged,100μl of plasma samples were separated in kit. Albuminlevels were measured by HITACHI7600-210automatic analyzer, CRPlevels were detected by BN-Ⅱ automatic analyzer of SiemensHealthcare Diagnostica. Then we collect the clinical data of each patient,and calculate the progression-free survival of patients (FPS), and overallsurvival (OS), etc.3. The clinical distributions of GPS/mGPS were analyzed by Fisherexact test. The prognostic date of patients were analyzed usingKaplan-Meier survival analysis, Log-Rank test, Cox proportional hazardsregression model, etc.Results:1. The distributions of GPS/mGPS were not correlated with gender,age, smoking status, histological type, ECOG score, clinical stage,first-line chemotherapy and Multi-line treatment plan.2. In the univariate analysis of PFS, we found that GPS/mGPS,histological type and first-line chemotherapy were associated with the PFS, but the gender, age, smoking status, ECOG score, clinical stage andmulti-line chemotherapy were not correlated with it.3. In the univariate analysis of OS, smoking status, histological type,multi-line chemotherapy were associated with the OS, GPS/mGPS,gender, age, ECOG score, clinical stage were not correlated with the OS.4. In the multivariate analysis of the PFS, it showed that GPS/mGPSof2was independent poor prognostic risk factors.5. In the multivariate analysis of the OS, It showed that GPS/mGPSof2, multi-line treatment were independent prognostic risk factors.Conclusions：1．The GPS system and the mGPS system can effectively predictprognosis of patients with advanced NSCLC， mGPS system is relativelymore convenient and concise.2．The GPS/mGPS system can evaluate prognosis for patients withadvanced non-small cell lung cancer, treated with cisplatin-basedfirst-line chemotherapy.3．The GPS/mGPS of2is an independent poor prognostic factor forpatients with advanced non-small cell lung cancer.